期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向药物在肝癌治疗中的应用 被引量：4

Application of Molecular Targeted Drugs in Therapy of Hepatocellular Carcinoma
原文传递
导出
摘要 肝癌是临床上最常见的恶性肿瘤之一,是世界上第5大常见肿瘤,在肿瘤致死原因中仅次于肺癌和胃癌,居第3位。肝癌的全球发病率逐年增长,发病人数超过62.6万人/年,死亡人数接近60万人/年。肝癌在组织病理学上分为3种类型,其中90%是肝细胞型肝癌（HCC）,另外10%为肝胆管细胞癌（ICC）和混合型肝癌（MHC）。由于起病隐袭,早期缺乏特异性症状。
作者 高军
机构地区 北京市第六医院普外科
出处 《中国普外基础与临床杂志》 CAS 2011年第5期560-563,共4页 Chinese Journal of Bases and Clinics In General Surgery
关键词 肝细胞癌 分子靶向治疗 索拉非尼 血管内皮生长因子 表皮生长因子
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献34

  • 1Parkin DM. Global cancer statistics in the year 2000 [J]. Lancet Oncol, 2001, 2(9): 533-543.
  • 2EI-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis [J]. Gastroenterology,2007, 132(7): 2557-2576.
  • 3Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma [J]. Nat Genet, 2002, 31 (4): 339-346.
  • 4Villanueva A, Minguez B, Forner A, et al. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy [J]. Annu Rev Med, 2010, 61: 317-328.
  • 5Tommasi S, Pinto R, Pilato B, et al. Molecular pathways and related target therapies in liver carcinoma[J]. Curr Pharm Des, 2007, 13(32): 3279-3287.
  • 6Llovet J, Ricci S, Mazzaferro V, etal. Sorafenib improves survival advanced, Results of a phase III randomized placebocontrolled trial [C]. 2007 ASCO Annual Meeting Proceeding Part 1 vol 25. No18S.
  • 7Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial [J]. Lancet Oncol, 2009, 10 (1) : 25-34.
  • 8Abou-Alfa GK, Schwartz L, Ricci S, etal. Phase II study of sorafenih in patients with advanced hepatocellular carcinoma[J]. JClinOncol, 2006, 24(26): 4293-4300.
  • 9Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis [J]. Oncologist, 2009, 14(1): 70-76.
  • 10Miller AA, Murry DJ, Owzar K, etal. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 [J]. J Clin Oncol, 2009, 27 (11) : 1800-1805.

同被引文献47

  • 1罗惠玲,黄炜,张志凌,吴其年,黄敏珊,张东方,杨凤仪.18β-glycyrrhetinic Acid-induced Apoptosis and Relation with Intracellular Ca^2＋ Release in Human Breast Carcinoma Cells[J].The Chinese-German Journal of Clinical Oncology,2004,3(3):137-140. 被引量：12
  • 2雍建平,张毓洪,赵巍,阿吉艾克拜尔.艾萨.甘草次酸及甘草次酸衍生物药理活性研究进展[J].时珍国医国药,2010,21(12):3335-3337. 被引量：13
  • 3宋燕,王凌燕,姜洋,高宇飞,吴广谋,朱平.LHRH-PE40对胃癌细胞增殖抑制和诱导凋亡的实验研究[J].中国老年学杂志,2006,26(7):928-929. 被引量：3
  • 4Abraham AK,Kagan L,Kumar S,et al.Type I interferon recep-tor is a primary regulator of target-mediated drug disposition of in-terferon-βin mice[J].J Pharmacol Exp Ther,2010,334(1):327-332.
  • 5Ruoslahti E,Bhatia SN,Sailor MJ.Targeting of drugs andnanoparticles to tumors[J].J Cell Biol,2010,188(6):759-768.
  • 6Betts AM,Clark TH,Yang JX,et al.The application of target in-formation and preclinical pharmacokinetic/pharmacodynamic model-ing in predicting clinical doses of a Dickkopf-1 antibody for osteo-porosis[J].J Pharmacol Exp Ther,2010,333(1):2-13.
  • 7Keller G,Schally AV,Gaiser T,et al.Receptors for luteinizinghormone releasing hormone expressed on human renal cell carci-nomas can be used for targeted chemotherapy with cytotoxicluteinizing hormone releasing hormone analogues[J].Clin Can-cer Res,2005,11(15):5549-5557.
  • 8Dharap SS,Wang Y,Chandna P,et al.Tumor-specific targetingof an anticancer drug delivery system by LHRH peptide[J].ProcNatl Acad Sci USA,2005,102(36):12962-12967.
  • 9Dharap SS,Minko T.Targeted proapoptotic LHRH-BH3 peptide[J].Pharm Res,2003,20(6):889-896.
  • 10郑艳军,郑艳霞,张国利.促黄体激素释放激素及其靶向毒素[J].中国生物制品学杂志,2007,20(10):786-788. 被引量：5

引证文献4

二级引证文献16

中国普外基础与临床杂志
2011年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部